Despite a significant net loss, GRAIL Inc (GRAL) reports strong revenue growth and strategic collaborations, setting the stage for future advancements.

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

Discover how Grail Inc. achieved 45% revenue growth, improved scalability with the updated Galleri test, and navigates legislative and market challenges.

The Robert De Niro-led Netflix conspiracy thriller has noble ambitions but an unsatisfactory message. Here's what happens in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Interim CEO Brent Shafer said the medical products maker is ready to begin a new era after several years of “heavy lifting” ...

Reports Q4 revenue $38.3M vs. $30.3M last year. “2024 was a transformational year for GRAIL (GRAL) as we completed the separation from Illumina ...

Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies ...